Merck, NanoBio team on preclinical RSV deal

Ann Arbor, MI-based NanoBio Corporation said it's teaming up with an unnamed Merck subsidiary on preclinical development of an intranasal vaccine for Respiratory Syncytial Virus (RSV). Researchers will be studying a combination of Merck's RSV antigen with NanoBio's NanoStat adjuvant technology. "RSV remains a major cause of serious lung infections in children and the elderly," said NanoBio founder and CEO James Baker, Jr. in a statement. "We look forward to working together in an effort to advance RSV vaccine research." NanoBio release

Suggested Articles

The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.